Your session is about to expire
← Back to Search
ALXN1850 for Hypophosphatasia (CHESTNUT Trial)
CHESTNUT Trial Summary
This trial will test if a new medication is safe and effective for children with a rare bone disease.
CHESTNUT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCHESTNUT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CHESTNUT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this experiment inviting seniors to participate?
"According to the stated requirements, eligible participants must be between 2 and 11 years old."
Are there any deleterious effects of taking ALXN1850?
"According to our assessment, ALXN1850's safety is rated at 3 because of the pre-existing evidence that supports its efficacy and multiple clinical trials attesting to its security."
Could I qualify to be included in this research project?
"The current clinical trial for hypophosphatasia treatment is accepting 30 participants between the ages of two and eleven."
How many locations are hosting this clinical investigation?
"At present, this clinical trial has 29 sites across the United States. These include Baltimore, Boston and Minneapolis among other cities. Therefore, it is wise to choose a location nearby in order to reduce travel costs when participating in the study."
Are new participants being accepted for this experiment?
"Per the information displayed on clinicaltrials.gov, this particular medical trial has ceased recruiting participants; it was initially posted on November 16th 2023 and its last update occurred October 6th 2023. Alternatively, there are presently 4 other trials that remain open for new enrollees."
Share this study with friends
Copy Link
Messenger